Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon.
Transmission of hepatitis C virus (HCV) in the setting of allogeneic bone marrow transplantation can occur through an infected marrow donor. Prevention of transmission may reduce the risks of peritransplant complications. We describe a 43-year-old patient with chronic myelogenous leukemia whose HLA-identical donor was found to be HCV antibody positive and HCV RNA positive by polymerase chain reaction (PCR). The patient was HCV antibody negative and HCV RNA negative by PCR of the serum. For 6 months before bone marrow transplantation, the donor was treated with alpha-interferon at a standard dose. After 3 months, HCV RNA was no longer detectable by PCR. Interferon was discontinued 1 week before harvest. Bone marrow cellularity was normal. Engraftment was prompt. The recipient's serum remained negative for HCV RNA at 1, 3, 5, and 10 months after transplantation. Hepatitis C transmission from a viremic donor to an HCV-seronegative recipient may be preventable by treating the donor with alpha-interferon.
Vance
E A
EA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02146, USA.
Soiffer
R J
RJ
McDonald
G B
GB
Myerson
D
D
Fingeroth
J
J
Ritz
J
J
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D006526:Hepatitis C / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D009679:Nuclear Family; D011994:Recombinant Proteins; D014019:Tissue Donors; D014184:Transplantation, Homologous
D011994:Recombinant Proteins; D007371:Interferon-gamma